• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全长致癌性 BRAF 的生化特性与分子动力学模拟为 RAF 激酶的激活和抑制机制提供了深入了解。

Biochemical Characterization of Full-Length Oncogenic BRAF together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases.

机构信息

Department of Chemistry and Biochemistry, University of the Sciences, Philadelphia, PA, 19104, USA.

Eukaryotic Tissue Culture Facility, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.

出版信息

Chembiochem. 2019 Nov 18;20(22):2850-2861. doi: 10.1002/cbic.201900266. Epub 2019 Oct 15.

DOI:10.1002/cbic.201900266
PMID:31152574
Abstract

The most prevalent BRAF mutation, V600E, occurs frequently in melanoma and other cancers. Although extensive progress has been made toward understanding the biology of RAF kinases, little in vitro characterization of full-length BRAF is available. Herein, we show the successful purification of active, full-length BRAF from mammalian cells for in vitro experiments. Our biochemical characterization of intact BRAF together with molecular dynamics (MD) simulations of the BRAF kinase domain and cell-based assays demonstrate that BRAF has several unique features that contribute to its tumorigenesis. Firstly, steady-state kinetic analyses reveal that purified BRAF is more active than fully activated wild-type BRAF; this is consistent with the notion that elevated signaling output is necessary for transformation. Secondly, BRAF has a higher potential to form oligomers, despite the fact that the V600E substitution confers constitutive kinase activation independent of an intact side-to-side dimer interface. Thirdly, BRAF bypasses inhibitory P-loop phosphorylation to enforce the necessary elevated signaling output for tumorigenesis. Together, these results provide new insight into the biochemical properties of BRAF , complementing the understanding of BRAF regulation under normal and disease conditions.

摘要

最常见的 BRAF 突变 V600E 频繁发生于黑色素瘤和其他癌症中。尽管人们在理解 RAF 激酶的生物学方面取得了广泛的进展,但对于全长 BRAF 的体外表征却知之甚少。在此,我们展示了从哺乳动物细胞中成功纯化出具有活性的全长 BRAF,可用于体外实验。我们对完整 BRAF 的生化特性以及 BRAF 激酶结构域的分子动力学 (MD) 模拟和基于细胞的测定表明,BRAF 具有几个独特的特征,有助于其肿瘤发生。首先,稳态动力学分析表明,纯化的 BRAF 比完全激活的野生型 BRAF 更具活性;这与升高的信号输出对于转化是必需的观点一致。其次,尽管 V600E 取代赋予了独立于完整侧向二聚体界面的组成型激酶激活,但 BRAF 具有更高形成寡聚体的潜力。第三,BRAF 绕过抑制性 P 环磷酸化,以强制产生致癌所需的升高的信号输出。总之,这些结果为 BRAF 的生化特性提供了新的见解,补充了在正常和疾病条件下对 BRAF 调节的理解。

相似文献

1
Biochemical Characterization of Full-Length Oncogenic BRAF together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases.全长致癌性 BRAF 的生化特性与分子动力学模拟为 RAF 激酶的激活和抑制机制提供了深入了解。
Chembiochem. 2019 Nov 18;20(22):2850-2861. doi: 10.1002/cbic.201900266. Epub 2019 Oct 15.
2
Resistance mechanism of the oncogenic β3-αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.通过分子动力学模拟和结合自由能计算揭示致癌性 BRAF 激酶β3-αC 缺失突变对 dabrafenib 和 vemurafenib 的耐药机制。
Chem Biol Drug Des. 2019 Feb;93(2):177-187. doi: 10.1111/cbdd.13399. Epub 2018 Oct 8.
3
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).RAF 抑制剂耐药性是由异常剪接的 BRAF(V600E)二聚化介导的。
Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.
4
Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.结肠癌中野生型和突变型BRAF激酶之间的化疗药物选择性
J Mol Model. 2017 Jan;23(1):1. doi: 10.1007/s00894-016-3177-8. Epub 2016 Dec 5.
5
Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF Conformation.化学连接的维莫非尼抑制剂促进BRAF的非活性构象。
ACS Chem Biol. 2016 Oct 21;11(10):2876-2888. doi: 10.1021/acschembio.6b00529. Epub 2016 Sep 6.
6
Analyses of the oncogenic BRAF variant reveal a kinase-independent function of BRAF in activating MAPK signaling.分析致癌 BRAF 变体揭示了 BRAF 在激活 MAPK 信号传导中激酶非依赖性的功能。
J Biol Chem. 2020 Feb 21;295(8):2407-2420. doi: 10.1074/jbc.RA119.011536. Epub 2020 Jan 12.
7
Mechanism of BRAF Activation through Biochemical Characterization of the Recombinant Full-Length Protein.通过重组全长蛋白的生化特性分析探讨 BRAF 激活的机制。
Chembiochem. 2018 Sep 17;19(18):1988-1997. doi: 10.1002/cbic.201800359. Epub 2018 Aug 17.
8
BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.BRAF 剪接变异体对 RAF 抑制剂的耐药性需要增强的 MEK 结合。
Cell Rep. 2018 Nov 6;25(6):1501-1510.e3. doi: 10.1016/j.celrep.2018.10.049.
9
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.针对人类癌症中致癌性 Raf 蛋白-丝氨酸/苏氨酸激酶。
Pharmacol Res. 2018 Sep;135:239-258. doi: 10.1016/j.phrs.2018.08.013. Epub 2018 Aug 15.
10
Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.BRAF(V600E)的分子动力学模拟及恶性黑色素瘤新型有效抑制剂的深入研究
Int J Nanomedicine. 2015 Apr 23;10:3131-46. doi: 10.2147/IJN.S80150. eCollection 2015.

引用本文的文献

1
Ion-DNA Interactions as a Key Determinant of Uracil DNA Glycosylase Activity.离子与DNA的相互作用是尿嘧啶DNA糖基化酶活性的关键决定因素。
Biochemistry. 2025 May 20;64(10):2332-2344. doi: 10.1021/acs.biochem.5c00067. Epub 2025 May 7.
2
Survey for Activating Oncogenic Mutation Variants in Metazoan Germline Genes.后生动物种系基因中致癌突变变体的激活调查。
J Mol Evol. 2024 Dec;92(6):930-943. doi: 10.1007/s00239-024-10218-4. Epub 2024 Nov 26.
3
Drug resistance in targeted cancer therapies with RAF inhibitors.使用RAF抑制剂的靶向癌症治疗中的耐药性。
Cancer Drug Resist. 2021 Jun 17;4(3):665-683. doi: 10.20517/cdr.2021.36. eCollection 2021.
4
The mechanism of activation of monomeric B-Raf V600E.单体B-Raf V600E的激活机制。
Comput Struct Biotechnol J. 2021 Jun 4;19:3349-3363. doi: 10.1016/j.csbj.2021.06.007. eCollection 2021.
5
Analyses of the oncogenic BRAF variant reveal a kinase-independent function of BRAF in activating MAPK signaling.分析致癌 BRAF 变体揭示了 BRAF 在激活 MAPK 信号传导中激酶非依赖性的功能。
J Biol Chem. 2020 Feb 21;295(8):2407-2420. doi: 10.1074/jbc.RA119.011536. Epub 2020 Jan 12.